The Trump administration has issued formal warnings to more than 500 hospitals across the United States for failing to publicly disclose their treatment prices, with facilities that do not act facing annual fines of up to $2 million per institution.

The enforcement drive is rooted in a 2019 executive order signed during Trump's first term. It targets a longstanding problem in American healthcare: patients, employers and insurers routinely have no way of knowing what a blood test, scan or surgical procedure will cost before it is carried out. A senior administration official confirmed that the warnings, which began in April, are part of a deliberate tightening of compliance standards, and that additional hospitals should expect to receive letters.

Texas recorded the highest number of flagged facilities, with 42 hospitals receiving warnings. Indiana followed with 34, a notable figure given that California, which has five times the population, received letters for 38 hospitals. Some of the country's most prominent institutions are on the list. The University of Texas MD Anderson Cancer Centre in Houston was among those flagged, though it said the issue amounted to a minor formatting error that had since been corrected and accepted by federal authorities.

The enforcement push carries clear political intent. The administration has positioned healthcare affordability as a defining issue ahead of November's midterm elections. The effort is not without risk, however. Trump faces criticism for allowing subsidies to lapse for people purchasing insurance through the Affordable Care Act, and only 29 per cent of American adults approved of his healthcare policies in the most recent survey by the Associated Press-NORC Centre for Public Affairs Research.

For British readers, the American debate may feel distant. NHS treatment remains free at the point of use, and most patients in England have no reason to think about what their care costs. But the question of price transparency is not entirely foreign to the UK. With NHS waiting lists still running into millions, a growing number of patients are turning to private providers, where pricing is often opaque and varies considerably between hospitals and procedures. Britons living or working in the United States are affected directly by the rules being enforced, and UK health policy professionals watch American market-based reform attempts closely, even when the conclusions drawn are cautionary ones.

The American Hospital Association said its members have long supported price transparency and that most hospitals are already meeting federal requirements. Ashley Thompson, its senior vice president for policy, acknowledged that the current system is not working as well as it could for patients. Missouri-based Ascension, one of the country's largest hospital groups, said warning letters it received related to a minor technical error and that it remained committed to patient information.

Analysts are cautious about how much the disclosures will help ordinary patients in practice. Gary Claxton of KFF, a health policy research organisation, said the data is currently more useful to benefit consultants and sector professionals than to individuals trying to compare costs. He noted that prices across the system appear more variable than a competitive market would ordinarily produce, and that greater transparency, while a step forward, does not yet allow for reliable like-for-like comparisons.

A congressional hearing on price transparency is scheduled this week before the House Committee on Energy and Commerce. The administration has indicated that more hospitals will receive warning letters in the coming period, suggesting the enforcement campaign remains in its early stages.

‍